Physician profile
Warren F Chumley
NPI 1902853617
$288,359.19
in general payments reported to CMS, 2019-2025
60 companies · $18K in 2025
The $18K reported for 2025 was more than what 91% of Clinical Neurophysiology providers received nationally (typical 2025 total: $435).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $66K · 2020: $44K · 2021: $64K · 2022: $53K · 2023: $24K · 2024: $20K · 2025: $18K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $47K · Food and Beverage: $8,051 · Honoraria: $3,850 · Travel and Lodging: $2,011 · Consulting Fee: $300 · Education: $12.01.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $46,837.50 |
| Food and Beverage | $8,050.79 |
| Honoraria | $3,850.00 |
| Travel and Lodging | $2,011.17 |
| Consulting Fee | $300.00 |
| Education | $12.01 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $103,944.15 | 2019-2025 | Qulipta, Ubrelvy, Botox |
| Allergan, INC. | $61,894.24 | 2019-2022 | |
| Amgen INC. | $30,991.33 | 2019-2021 | |
| Teva Pharmaceuticals USA, INC. | $26,565.81 | 2019-2025 | Austedo Xr, Ajovy, Austedo Xr |
| Lilly USA, LLC | $16,760.17 | 2019-2025 | Emgality, Reyvow, Kisunla |
| Biohaven Pharmaceuticals, INC. | $11,888.86 | 2020-2021 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $9,032.58 | 2022 | |
| Lundbeck LLC | $5,579.98 | 2019-2025 | Vyepti |
| Mallinckrodt Enterprises LLC | $4,487.05 | 2019 | |
| Alexion Pharmaceuticals, INC. | $4,421.53 | 2019-2025 | Ultomiris |
| Axsome Therapeutics, INC. | $4,004.25 | 2023-2025 | Symbravo, Sunosi |
| Novartis Pharmaceuticals Corporation | $1,177.26 | 2019-2025 | |
| Pfizer INC. | $1,019.74 | 2019-2025 | |
| Biogen, INC. | $796.51 | 2019-2025 | Tysabri, Vumerity, Leqembi |
| Genzyme Corporation | $528.46 | 2019-2025 |
Show all 58 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $527.27 | 2019-2025 | |
| Emd Serono, INC. | $400.55 | 2019-2025 | Mavenclad, Mavenclad |
| Ucb, INC. | $395.06 | 2019-2020 | |
| Celgene Corporation | $383.15 | 2021-2025 | Zeposia |
| Genentech, INC. | $340.75 | 2019-2024 | Xolair |
| Acadia Pharmaceuticals INC | $304.73 | 2019-2025 | Nuplazid |
| Vanda Pharmaceuticals INC. | $276.04 | 2024-2025 | Ponvory |
| Sk Life Science, INC. | $249.20 | 2022-2025 | Xcopri |
| Csl Behring | $238.15 | 2019-2025 | Hizentra |
| Neurocrine Biosciences, INC. | $214.75 | 2019-2023 | Ongentys, Ingrezza |
| Genentech USA, INC. | $202.47 | 2019-2025 | Ocrevus, Ocrevus Zunovo |
| Takeda Pharmaceuticals U.S.A., INC. | $179.04 | 2024-2025 | Hyqvia |
| Sunovion Pharmaceuticals INC. | $154.29 | 2019-2020 | |
| Jazz Pharmaceuticals INC. | $141.70 | 2019-2025 | |
| Sanofi-Aventis U.S. LLC | $133.74 | 2019-2020 | |
| Novo Nordisk INC | $118.99 | 2025 | |
| Amneal Pharmaceuticals LLC | $91.15 | 2024-2025 | Rytary, Crexont |
| Avanir Pharmaceuticals, INC. | $84.09 | 2019 | |
| Azurity Pharmaceuticals, INC. | $76.91 | 2024-2025 | Horizant |
| Merz North America, INC. | $68.45 | 2019 | |
| Tg Therapeutics, INC. | $62.38 | 2025 | |
| Argenx US, INC. | $59.70 | 2024-2025 | Vyvgart |
| Akcea Therapeutics, INC. | $51.66 | 2019 | |
| Merz Pharmaceuticals, LLC | $49.07 | 2024 | Xeomin, Inbrija |
| Grifols USA, LLC | $47.65 | 2024 | Gamunex-C |
| Mdd US Operations, LLC | $45.89 | 2019-2024 | Gocovri |
| Promius Pharma LLC | $39.07 | 2019 | |
| Boston Scientific Corporation | $36.09 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $33.72 | 2022-2023 | Ponvory |
| Arbor Pharmaceuticals, INC. | $31.36 | 2019-2020 | |
| Catalyst Pharmaceuticals, INC. | $27.51 | 2024 | |
| Otsuka America Pharmaceutical, INC. | $25.06 | 2025 | Rexulti |
| Octapharma USA, INC. | $21.73 | 2025 | Panzyga |
| Ani Pharmaceuticals, INC. | $20.35 | 2024 | Purified Cortrophin Gel |
| Livanova USA, INC. | $17.60 | 2025 | Vns Therapy Sentiva Model 1000 Generator |
| Cala Health, INC. | $17.35 | 2025 | Cala Kiq |
| Acorda Therapeutics, INC | $16.85 | 2019 | |
| Vertical Pharmaceuticals, LLC | $16.41 | 2019 | |
| Upsher-Smith Laboratories LLC | $15.80 | 2020 | |
| Neuronetics, INC. | $13.18 | 2019 | |
| Aprecia Pharmaceuticals, LLC | $13.02 | 2020 | |
| Zyla Life Sciences, INC. | $12.88 | 2019 | |
| Supernus Pharmaceuticals, INC. | $12.46 | 2020 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Warren Chumley listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.